Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap USD M58.6Revenue (TTM) USD M--Net Margin (%)--Altman Z-Score-11.0
Enterprise Value USD M49.2EPS (TTM) USD -0.8Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book14.610-y EBITDA Growth Rate %-5.8Quick Ratio3.9Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %5.0Current Ratio3.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-102.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-191.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M32.2ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GALT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

GALT is held by these investors:



GALT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CZIRR JAMES CDirector 2016-04-20Sell44,312$1.678.98view
10X Fund, L.P.10% Owner 2016-04-20Sell44,312$1.678.98view
10X Fund, L.P.10% Owner 2016-04-20Sell44,312$1.6510.3view
CZIRR JAMES CDirector 2016-04-20Sell44,312$1.6510.3view
Greenberg ArthurDirector 2016-01-05Buy1,666$1.725.81view
AMELIO GILBERT FDirector 2015-11-30Sell100$2.1-13.33view
TRABER PETER GPresident & CEO 2015-08-12Buy2,000$2-9view
TRABER PETER GPresident & CEO 2015-06-01Buy4,000$2.53-28.06view
FREEMAN KEVIN DDirector 2015-06-01Buy2,083$2.7-32.59view
AMELIO GILBERT FDirector 2014-12-15Sell110$3.69-50.68view

Press Releases about GALT :

Quarterly/Annual Reports about GALT:

News about GALT:

Articles On GuruFocus.com
No related article found.

More From Other Websites
Bull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and... Feb 22 2017
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Feb 17 2017
Galectin Therapeutics to Present at BIO CEO & Investor Conference Feb 08 2017
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 07 2017
Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models... Feb 07 2017
Galectin Therapeutics Presentation Now Available for On-Demand Viewing Feb 06 2017
Galectin Therapeutics Presentation Now Available for On-Demand Viewing Feb 06 2017
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 02 2017
Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial Feb 01 2017
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 01 2017
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present... Jan 30 2017
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present... Jan 30 2017
Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2 Jan 30 2017
Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2 Jan 30 2017
Galectin Therapeutics Announces $4 Million in New Equity Financings Dec 29 2016
Galectin Therapeutics Announces $4 Million in New Equity Financings Dec 29 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 29 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 20 2016
Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders Dec 08 2016
GALECTIN THERAPEUTICS INC Financials Nov 15 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)